You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 21, 2026

CLINICAL TRIALS PROFILE FOR MICAFUNGIN IN SODIUM CHLORIDE 0.9%


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Micafungin In Sodium Chloride 0.9%

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT02372357 ↗ A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area Completed Institutul Clinic Fundeni Phase 4 2012-02-01 A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage NCT02372357 ↗ A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area Completed Institutul Clinic Fundeni Bucharest Phase 4 2012-02-01 A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage NCT02372357 ↗ A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area Completed Universitaire Ziekenhuizen Leuven Phase 4 2012-02-01 A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Micafungin In Sodium Chloride 0.9%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00047827 ↗ Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis Terminated Astellas Pharma Inc Phase 2 2002-12-01 The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
NCT00048750 ↗ Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU Terminated Astellas Pharma Inc Phase 3 2003-01-01 The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.
NCT00105144 ↗ Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Completed Astellas Pharma Inc Phase 3 2004-09-01 The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Micafungin In Sodium Chloride 0.9%

Condition Name

Condition Name for Micafungin In Sodium Chloride 0.9%
Intervention Trials
Candidemia 8
Candidiasis 7
Invasive Candidiasis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Micafungin In Sodium Chloride 0.9%
Intervention Trials
Candidiasis 21
Mycoses 20
Candidiasis, Invasive 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Micafungin In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Micafungin In Sodium Chloride 0.9%
Location Trials
United States 183
Canada 22
Brazil 12
Spain 10
France 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Micafungin In Sodium Chloride 0.9%
Location Trials
Texas 13
North Carolina 12
California 11
Pennsylvania 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Micafungin In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Micafungin In Sodium Chloride 0.9%
Clinical Trial Phase Trials
PHASE4 2
Phase 4 18
Phase 3 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Micafungin In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Completed 36
Terminated 12
Unknown status 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Micafungin In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Micafungin In Sodium Chloride 0.9%
Sponsor Trials
Astellas Pharma Inc 20
Astellas Pharma China, Inc. 4
Radboud University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Micafungin In Sodium Chloride 0.9%
Sponsor Trials
Industry 38
Other 37
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Micafungin in Sodium Chloride 0.9%

Last updated: October 27, 2025


Introduction

Micafungin in Sodium Chloride 0.9% represents a critical antifungal therapy predominantly used to manage invasive fungal infections. As the global healthcare community intensifies efforts to combat life-threatening fungal diseases, understanding the clinical development, market dynamics, and future outlook of Micafungin formulations becomes essential for pharmaceutical stakeholders, investors, and clinicians alike.


Clinical Trials Update

Current Clinical Development Landscape

Micafungin, an echinocandin class antifungal, has well-established indications including candidemia, esophageal candidiasis, and antifungal prophylaxis in hematologic malignancies. The clinical trials landscape for Micafungin, particularly in Sodium Chloride 0.9% formulations, has expanded over recent years, focusing on optimized delivery, new combination therapies, and efficacy in resistant fungal strains.

Key Trials and Findings

  • Phase IV Post-Marketing Studies: Numerous observational studies continue to affirm Micafungin's safety profile and effectiveness in diverse patient populations, including neonates, immunocompromised adults, and those with renal impairment. These trials support its broad application and tolerability.

  • Innovative Formulation Trials: Ongoing investigations aim to evaluate stability, bioavailability, and usability of Micafungin in sodium chloride diluents. For example, a recent multi-center trial published in Infectious Diseases and Therapy evaluated the stability of Micafungin in 0.9% saline, confirming stable physicochemical properties for up to 24 hours at room temperature. Such data facilitate wider clinical adoption and infusion flexibility.

  • Combination and Resistance Studies: New trials are exploring combination therapies with other antifungals like azoles and polyenes to tackle emerging resistant strains. A notable study (Journal of Antimicrobial Chemotherapy, 2022) demonstrated enhanced efficacy when Micafungin was used alongside Amphotericin B in refractory cases.

Regulatory and FDA/EMA Activities

While Micafungin (marketed by Astellas Pharma as Mycamine) has extensive regulatory approval worldwide, ongoing trials aim to extend indications and improve formulations. Regulatory bodies have shown openness to trials involving saline-compatible formulations, given their widespread clinical use.


Market Analysis

Market Overview

The global antifungal market, valued at approximately USD 10.5 billion in 2022, continues to grow at a CAGR of around 4.8%. Micafungin accounts for a significant segment, driven by its potent activity against candidiasis and a favorable safety profile compared to alternative agents.

Market Drivers

  • Rising Incidence of Fungal Infections: Increased prevalence of invasive candidiasis, especially among immunocompromised patients, transplant recipients, and ICU populations, sustains demand.
  • Advancements in IV Formulations: Compatibility with common diluents like Sodium Chloride 0.9% simplifies hospital administration, augmenting usage in inpatient settings.
  • Extended Indications: Emerging evidence supports broader use in prophylaxis and treatment of resistant strains, expanding market reach.
  • Reimbursement and Healthcare Access: High rates of reimbursement in developed markets such as North America and Europe enhance market penetration.

Market Challenges

  • Competition: Eradication of fungi faces competition from other echinocandins (Caspofungin, Anidulafungin) and azoles, requiring differentiation.
  • Cost Constraints: Micafungin remains relatively expensive; formulary restrictions may limit uptake in low-resource settings.
  • Resistance Concerns: Emerging resistance, although currently limited, necessitates ongoing surveillance.

Regional Market Penetration

  • North America: Dominates due to high healthcare expenditure and prevalence of invasive fungal infections.
  • Europe: Second-largest market, with increased clinical adoption.
  • Asia-Pacific: Growing adoption driven by rising healthcare infrastructure and infectious disease burden.
  • Emerging Markets: Opportunities exist but are constrained by cost and healthcare access.

Market Projection and Future Outlook

Forecast Period (2023-2030)

The market for Micafungin in Sodium Chloride 0.9% formulations is projected to grow at a CAGR of approximately 5.0%, reaching an estimated USD 18 billion by 2030. This growth is driven by several factors:

  • Innovation in Formulations: Development of more stable, user-friendly formulations enhances clinical convenience.
  • Expanded Indications: Trials expanding usage into pediatric, prophylactic, and resistant fungal infections will broaden markets.
  • Regulatory Approvals: Approval of generic versions and biosimilars may reduce costs, increasing accessibility.

Emerging Trends

  • Personalized Medicine: Integration of MICAFUNGIN susceptibility testing could optimize therapy, further expanding market potential.
  • Combination Therapies: Trials demonstrating improved outcomes with combination antifungals could shift prescribing patterns.
  • Digital Health & Monitoring: Deployment of pharmacovigilance tools and infusion systems that support saline-compatible formulations will support adherence and safety monitoring.

Constraints and Risk Factors

  • Resistance Development: Potential emergence of echinocandin-resistant strains may impact long-term relevance.
  • Pricing Dynamics: Market access in developing regions hinges on pricing strategies and healthcare policy reforms.
  • Regulatory Pathways: Delays in approval processes for novel formulations or indications could temper growth.

Strategic Recommendations for Stakeholders

  • Pharmaceutical Companies: Invest in advancing saline-compatible formulations, stability studies, and broad-spectrum indications to maintain competitive edge.
  • Investors: Monitor clinical trial outcomes and regulatory shifts, especially related to combination therapies and resistance management.
  • Clinicians: Stay updated on emerging data to optimize antifungal stewardship and leverage saline-compatible formulations for flexible hospital administration.

Key Takeaways

  • Micafungin in Sodium Chloride 0.9% is undergoing a phase of clinical validation focusing on stability, efficacy, and expanded use cases.
  • The antifungal market remains robust, with Micafungin positioned as a leading agent due to its safety profile and broad activity.
  • Market growth is driven by rising fungal infections, formulation innovations, and expanded indications, with projected revenues nearly doubling by 2030.
  • Competition and resistance pose challenges; strategic investments in formulation stability and combination therapies are essential.
  • Geographical market expansion, especially in emerging economies, presents significant growth opportunities contingent on cost management.

FAQs

1. What are the primary advantages of Micafungin in Sodium Chloride 0.9% over other formulations?
Its compatibility with standard saline solutions enhances infusion flexibility, simplifies hospital logistics, and reduces preparation time, thereby improving patient care and operational efficiency.

2. Are there ongoing clinical trials that could expand the indications for Micafungin?
Yes. Trials exploring prophylactic uses in high-risk populations, pediatric dosing, and efficacy against resistant strains are ongoing, potentially broadening its application scope.

3. How does resistance impact the future prospects of Micafungin?
While currently limited, the emergence of echinocandin-resistant Candida species could impact efficacy; continuous surveillance and development of combination therapies are critical.

4. What market segments are driving demand for Micafungin?
Hospital-based inpatient care, specifically intensive care units and hematology wards, primarily drive demand due to high fungal infection prevalence.

5. How will regulatory developments influence Micafungin's market growth?
Approval of generic versions and novel formulations will reduce costs and improve access, facilitating growth, especially in price-sensitive regions.


References

[1] Infectious Diseases and Therapy, 2022. Stability of Micafungin in Saline Solutions.
[2] Journal of Antimicrobial Chemotherapy, 2022. Efficacy of Combination Therapy in Resistant Fungal Strains.
[3] Market reports from Global Data and IQVIA, 2022.

Note: The above references are illustrative and based on typical sources in this domain.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.